培養脂肪細胞の異なるステージでの脂肪細胞形成に対するプロスタサイクリンの特異的作用 by Khan, Ferdous
㸦Format  No. 13㸧 
SUMMARY OF DOCTORAL THESIS 
 
                                               Name:  Ferdous Khan 
 
Title:  Specific action of prostacyclin on adipogenesis at different stages  
of cultured adipocytes 
㸦ᇵ㣴⬡⫫⣽⬊ࡢ␗࡞ࡿࢫࢸ࣮ࢪ࡛ࡢ⬡⫫⣽⬊ᙧᡂ࡟ᑐࡍࡿࣉࣟࢫࢱࢧ࢖ࢡࣜࣥࡢ
≉␗ⓗస⏝㸧 
 
 
     The present study attempted to clarify the specific action of prostacyclin, alternatively termed 
prostaglandin (PG) I2, on adipogenesis at different stages of cultured adipocytes from two points of 
view. Initially, I studied the influence of pretreatment of cultured preadipocytes with arachidonic 
acid during the differentiation phase without a cAMP-elevating agent on adipogenesis after the 
maturation phase. Next research was conducted to unravel the effects of prostacyclin and selective 
agonists of prostanoid IP receptor on the storage of fats during the maturation phase of cultured 
adipocytes.  
     Arachidonic acid (AA), a member of n-6 polyunsaturated fatty acids, can be converted to 
several prostanoids with pro-adipogenic or anti-adipogenic effects through the arachidonate 
cyclooxygenase (COX) pathway with two types of COX isoforms, the rate-limiting enzymes of this 
pathway. Preadipogenic mouse 3T3-L1 cells have been utilized as a useful model cell culture system 
for studying different life stages of adipogenesis under the defined cultured conditions including 
growth, differentiation, and maturation phases. Recent studies have established that PGE2 and PGF2D 
are synthesized preferentially in cultured 3T3-L1 preadipocytes and serve as anti-adipogenic 
prostanoids. On the other hand, previous studies have reported the selective expression of 
lipocalin-type PGD synthase necessary for the biosynthesis of PGD2 after the maturation phase of 
cultured 3T3-L1 cells. PGD2 readily undergo the non-enzymatic dehydration to give biologically 
active PGJ2 derivatives including 15-deoxy-'12,14-PGJ2 (15d-PGJ2) and '12-PGJ2. Of these, 
15d-PGJ2 is the most potent natural activator for the nuclear hormone receptor, peroxisome 
proliferator-activated receptor (PPAR)J. We have also shown that cultured adipocytes after the 
maturation phase have the ability to increasingly produce endogenous PGs of J2 series and contribute 
to the up-regulation of adipogenesis. Therefore, PGD2 and the related PGJ2 derivatives can be 
regarded as pro-adipogenic prostanoids. More recently, we have reported that endogenous synthesis 
of prostacyclin, PGI2, is also positively regulated after the maturation phase of cultured 3T3-L1 
adipocytes. Cultured 3T3-L1 preadipocytes have been usually exposed to the differentiation medium 
supplemented with 3-isobutyl-1-methylxanthine (IBMX), insulin, and dexamethasone to induce the 
program to drive the resting cells into adipocytes. The addition of exogenous AA to the 
differentiation medium has been shown to suppress the differentiation of cultured 3T3-L1 
preadipocytes. On the other hand, earlier reports described that exogenous AA in the culture medium 
without IBMX was effective to induce the differentiation of Ob1771 preadipose cells and 
3T3-F442A cells. Hence, we hypothesized that the opposite effects of exogenous AA on 
adipogenesis in different cell lines could be explained by presence or absence of IBMX, a cAMP 
elevating agent.  
     AA and the related prostanoids exert complex effects on the adipocyte differentiation 
depending on the culture conditions and life stages. Here, I investigated the effect of the pretreatment 
of cultured 3T3-L1 preadipocytes with exogenous AA during the differentiation phase without 
IBMX, a cAMP-elevating agent, on the storage of fats after the maturation phase. This pretreatment 
with AA stimulated appreciably adipogenesis after the maturation phase as evident with the 
up-regulated gene expression of adipogenic markers. The stimulatory effect of the pretreatment with 
AA was attenuated by the co-incubation with each of COX inhibitors. Among exogenous prostanoids 
and related compounds, the pretreatment with MRE-269, a selective agonist of the IP receptor for 
PGI2, strikingly stimulated the storage of fats in adipocytes. The gene expression analysis of 
arachidonate COX pathway revealed that the transcript levels of inducible COX-2, membrane-bound 
PGE synthase-1, and PGF synthase declined more greatly in cultured preadipocytes treated with AA. 
By contrast, the expression levels of COX-1, cytosolic PGE synthase, and PGI synthase remained 
constitutive. The treatment of cultured preadipocytes with AA resulted in the decreased synthesis of 
PGE2 and PGF2D serving as anti-adipogenic PGs although the biosynthesis of pro-adipogenic PGI2 
was up-regulated during the differentiation phase. Moreover, the gene expression levels of EP4 and 
FP, the respective prostanoid receptors for PGE2 and PGF2D, were gradually suppressed by the 
supplementation with AA, whereas that of IP for PGI2 remained relatively constant. Collectively, 
these results suggest the predominant role of endogenous PGI2 in the stimulatory effect of the 
pretreatment of cultured preadipoccytes with AA during the differentiation phase without IBMX on 
adipogenesis after the maturation phase.  
     Earlier studies described that carbaprostacyclin, a stable analogue of PGI2 also called 
prostacyclin, exerted pro-adipogenic effects on Ob1771 mouse-pre-adipose cells. Alternatively, 
growing 3T3-L1 cells have been reported to produce PGI2 upon acute stimulation with calcium 
ionophore A23187. More recently we have provided the evidence that cultured 3T3-L1 adipocytes 
during the maturation phase are more capable of generating endogenous PGI2 as determined by the 
amount of 6-keto-PGF1D as the stable hydrolysis product of PGI2 by its specific immunological 
assay, which is accompanied by the coordinated gene expression of PGI synthase and the prostanoid 
IP receptor for PGI2. These findings lead us to suggest the pro-adipogenic action of endogenous PGI2 
as an autocrine factor in mature adipocytes. However, the action of natural PGI2 appears to be 
uncertain due to the short half-life in biological fluids. By the extension of our recent results, we aim 
to obtain more insight into the role for prostacyclin and the related compounds in the up-regulation 
of adipogenesis in cultured adipocytes during the maturation phase. In this study, I tried to determine 
the specific action of the parent prostacylin and the related agonists or antagonists for the specific IP 
receptor on adipogenesis in combination with the agents that influence the activation of PPARJ and 
the elevation of cAMP. We discuss the mode of how prostacylin affects adipogenesis through the IP 
receptor during the maturation phase of adipocytes   
     My laboratory has previously shown that cultured adipocytes have the ability to biosynthesize 
PGI2 called alternatively as prostacyclin during the maturation phase by the positive regulation of 
gene expression of PGI synthase and the prostanoid IP receptor. To clarify how prostacyclin 
regulates adipogenesis, I investigated the effects of prostacyclin and the specific agonists or 
antagonists for the IP receptor on the storage of fats during the maturation phase of cultured 
adipocytes. Exogenous PGI2 and the related selective agonists for the IP receptor including 
MRE-269 and treprostinil rescued the storage of fats attenuated by aspirin, a COX inhibitor. On the 
other hand, selective antagonists for IP such as CAY10441 and CAY10449 were effective to 
suppress the accumulation of fats as GW9662, a specific antagonist for PPARJ. Thus, 
pro-adipogenic action of prostacyclin can be explained by the action mediated through the IP 
receptor expressed at the maturation stage of adipocytes. Cultured adipocytes incubated with each of 
PGI2 and MRE-269 together with troglitazone, an activator for PPARJ, exhibited additively higher 
stimulation of fats storage than with either compound alone. The combined effect of MRE-269 and 
troglitazone was almost abolished by co-incubation with GW9662, but not with CAY10441. 
Increasing concentrations of troglitazone were found to reverse the inhibitory effect of CAY10441 in 
a dose-dependent manner while those of MRE-269 failed to rescue adipogenesis suppressed by 
GW9662, indicating the critical role of the PPARJ activation as a downstream factor for the 
stimulated adipogenesis through the IP receptor. Treatment of cultured adipocytes with cell 
permeable stable cAMP analogues or forskolin as a cAMP elevating agent partly restored the 
inhibitory effect of aspirin. However, excess levels of cAMP stimulated by forskolin attenuated 
adipogenesis. Supplementation with H-89, a cell permeable inhibitor for protein kinase A (PKA), 
had no effect on the promoting action of PGI2 or MRE-269 along with aspirin on the storage of fats, 
suggesting that the promotion of adipogenesis mediated by the IP receptor does not require the PKA 
activity.     
 
